W
Wilfredo F. Garcia-Beltran
Researcher at Harvard University
Publications - 40
Citations - 4634
Wilfredo F. Garcia-Beltran is an academic researcher from Harvard University. The author has contributed to research in topics: Immune system & Medicine. The author has an hindex of 14, co-authored 27 publications receiving 1739 citations. Previous affiliations of Wilfredo F. Garcia-Beltran include Massachusetts Institute of Technology & Heinrich Pette Institute.
Papers
More filters
Journal ArticleDOI
Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.
Wilfredo F. Garcia-Beltran,Wilfredo F. Garcia-Beltran,Evan C. Lam,Kerri St. Denis,Adam Nitido,Zeidy H. Garcia,Blake M. Hauser,Jared Feldman,Maia N. Pavlovic,David Gregory,Mark C. Poznansky,Alex Sigal,Alex Sigal,Aaron G. Schmidt,A. John Iafrate,Vivek Naranbhai,Vivek Naranbhai,Alejandro B. Balazs +17 more
TL;DR: In this article, the authors evaluated the neutralization potency of 99 individuals that received one or two doses of either BNT162b2 or mRNA-1273 vaccines against pseudoviruses representing 10 globally circulating strains of SARS-CoV-2.
Journal ArticleDOI
mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant
Wilfredo F. Garcia-Beltran,K. S. St. Denis,Angelique Hoelzemer,Evan C. Lam,Adam Nitido,M. Sheehan,Cristhian Berríos,Onosereme Ofoman,Christina C. Chang,Blake M. Hauser,Jared Feldman,Alex Roederer,David Gregory,Mark C. Poznansky,Aaron G. Schmidt,A. John Iafrate,Vivek Naranbhai,Alejandro B. Balazs +17 more
TL;DR: In this article , the authors measured the neutralization potency of sera from 88 mRNA-1273, 111 BNT162b, and 40 Ad26.1.1/B.COV2.
Journal ArticleDOI
COVID-19-neutralizing antibodies predict disease severity and survival.
Wilfredo F. Garcia-Beltran,Evan C. Lam,Michael G Astudillo,Diane Yang,Tyler E. Miller,Jared Feldman,Blake M. Hauser,Timothy M. Caradonna,Kiera L. Clayton,Adam Nitido,Mandakolathur R. Murali,Galit Alter,Richelle C. Charles,Anand S. Dighe,John A. Branda,Jochen K. Lennerz,Daniel Lingwood,Aaron G. Schmidt,A. John Iafrate,Alejandro B. Balazs +19 more
TL;DR: It is found that severe cases resulting in intubation or death exhibited increased inflammatory markers, lymphopenia, pro-inflammatory cytokines, and high anti-receptor binding domain (RBD) antibody levels, highlighting the importance of neutralizing humoral immunity on disease progression and the need to develop broadly protective interventions to prevent future coronavirus pandemics.
Journal ArticleDOI
Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients.
Anita S. Iyer,Forrest K. Jones,Ariana Nodoushani,Meagan Kelly,Margaret Becker,Damien Slater,Rachel Mills,Erica Teng,Mohammad Kamruzzaman,Wilfredo F. Garcia-Beltran,Michael G Astudillo,Diane Yang,Tyler E. Miller,Elizabeth Oliver,Stephanie Fischinger,Caroline Atyeo,A. John Iafrate,Stephen B. Calderwood,Stephen A. Lauer,Jingyou Yu,Zhenfeng Li,Jared Feldman,Blake M. Hauser,Timothy M. Caradonna,John A. Branda,Sarah E Turbett,Regina C. LaRocque,Guillaume Mellon,Dan H. Barouch,Dan H. Barouch,Aaron G. Schmidt,Aaron G. Schmidt,Andrew S. Azman,Galit Alter,Edward T. Ryan,Jason B. Harris,Richelle C. Charles +36 more
TL;DR: RBD-targeted antibodies are excellent markers of previous and recent infection, that differential isotype measurements can help distinguish between recent and older infections, and that IgG responses persist over the first few months after infection and are highly correlated with neutralizing antibodies.
Posted ContentDOI
Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.
Wilfredo F. Garcia-Beltran,Wilfredo F. Garcia-Beltran,Evan C. Lam,Kerri St. Denis,Adam Nitido,Zeidy H. Garcia,Blake M. Hauser,Jared Feldman,Maia N. Pavlovic,David Gregory,Mark C. Poznansky,Alex Sigal,Alex Sigal,Aaron G. Schmidt,A. John Iafrate,Vivek Naranbhai,Alejandro B. Balazs +16 more
TL;DR: In this article, the authors evaluated the neutralization potency of 99 individuals that received one or two doses of either BNT162b2 or mRNA-1273 vaccines against 10 globally circulating strains of SARS-CoV-2.